Literature DB >> 12139565

Lipid parameters in childhood cirrhosis and chronic liver disease.

Mukadder Ayşe Selimoglu1, Sema Aydogdu, Rasit Vural Yagci.   

Abstract

BACKGROUND: Alterations in lipid metabolism are well defined in liver disease. As there has not been an ample amount of work published regarding this topic in children, especially about apolipoprotein A-I (apo A-I) and apolipoprotein B (apo B), theoretical knowledge depends on adult studies. In this study, we investigated serum lipid parameters of children with chronic liver disease and cirrhosis.
METHODS: Serum triglyceride, cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), plasma apo A-I and apo B levels of 82 children with chronic liver disease, 41 of whom had cirrhosis as well, were investigated. Twenty healthy children were selected as controls.
RESULTS: While mean serum triglyceride and cholesterol levels were not different in chronic hepatitis, cirrhosis and healthy children, mean apo B level of cirrhotic group was higher than that of the control group (P < 0.05). Mean LDL and HDL values of children with chronic hepatitis were lower and mean apo B value was higher than those of the control group (P < 0.05, P < 0.05 and P < 0.001, respectively). Apolipoprotein A-I level was lower in cholestatic cirrhotic children than non-cholestatic children (P < 0.05). No statistical difference was detected in lipid parameters of children with or without malnutrition (P > 0.05). The mean HDL value of Child-Pugh B group was significantly lower when compared to Child-Pugh A group (P < 0.05). The mean apo A-I value of Child-Pugh A group was higher than those of Child-Pugh B and C groups (P < 0.05 and P < 0.001).
CONCLUSION: Consequently, we found that among lipid parameters apo A-I was the most affected parameter in liver injury. Whether apo A-I level can be used as a prognostic criterion in childhood cirrhosis may require further study.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12139565     DOI: 10.1046/j.1442-200x.2002.01590.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  6 in total

1.  Serum arylesterase and paraoxonase activity in patients with chronic hepatitis.

Authors:  Suleyman Sirri Kilic; Suleyman Aydin; Nermin Kilic; Fazilet Erman; Suna Aydin; Ilhami Celik
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

2.  Non-alcoholic Fatty Liver Disease in Morbidly Obese Individuals Undergoing Bariatric Surgery: Prevalence and Effect of the Pre-Bariatric Very Low Calorie Diet.

Authors:  Katherine J P Schwenger; Sandra E Fischer; Timothy D Jackson; Allan Okrainec; Johane P Allard
Journal:  Obes Surg       Date:  2018-04       Impact factor: 4.129

3.  Low plasma apolipoprotein A-I level is not a reliable marker of fibrosis in children with chronic hepatitis B.

Authors:  Mukadder-Ayse Selimoglu; Rasit-Vural Yagcl; Gül Yüce
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

4.  The relationship between lipid profile and severity of liver damage in cirrhotic patients.

Authors:  Mohammad Reza Ghadir; Ali Akbar Riahin; Abbas Havaspour; Mehrdad Nooranipour; Abbas Ali Habibinejad
Journal:  Hepat Mon       Date:  2010-12-01       Impact factor: 0.660

5.  The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins.

Authors:  Lech Chrostek; Lukasz Supronowicz; Anatol Panasiuk; Bogdan Cylwik; Ewa Gruszewska; Robert Flisiak
Journal:  Clin Exp Med       Date:  2014-11       Impact factor: 3.984

6.  Frankincense essential oil suppresses melanoma cancer through down regulation of Bcl-2/Bax cascade signaling and ameliorates heptotoxicity via phase I and II drug metabolizing enzymes.

Authors:  Faruck L Hakkim; Hamid A Bakshi; Shabia Khan; Mohamad Nasef; Rabia Farzand; Smitha Sam; Luay Rashan; Mohammed S Al-Baloshi; Sidgi Syed Anwar Abdo Hasson; Ali Al Jabri; Paul A McCarron; Murtaza M Tambuwala
Journal:  Oncotarget       Date:  2019-05-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.